XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.98

-0.7%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	9/13/2008 3:31:16 AM
	of 17367

thestreet.com / feuerstein.. "...John R. took a look at the new diabetes data from Xoma's(XOMA Quote - Cramer on XOMA - Stock Picks) lead drug XOMA 052 released this week and asked, "Is this as revolutionary as I think it is? Why am I the only one to think this is huge?" XOMA 052 would be revolutionary and huge if the drug is proven to work against diabetes. We're not there yet, although Monday's data was a nice start. XOMA 052 is an intravenous monoclonal antibody that targets interleukin-1 beta, a pro-inflammatory protein that is thought to play a role in diabetes, rheumatoid arthritis and other diseases. XOMA 052 binds to IL-1 beta, thereby preventing inflammation that can damage insulin-producing islet cells in the pancreas. This is a unique approach to diabetes care. Or so Xoma hopes. Interim data from a phase I study of Type 2 diabetes patients presented Monday at a European diabetes conference were encouraging, with patients across multiple dose groups showing evidence of biological activity, measured by decreases in blood glucose levels and biomarkers suggestive of increased insulin production and reductions in systemic inflammation. There's a lot more work to do on XOMA 052, including final data from this study next year followed by new multi-dosing studies. XOMA 052 is given intravenously once a month, so it has the potential to be very convenient for patients. (Even more so if the company can develop a version that can be given via subcutaneous injection.) All in all, this was a good week for Xoma. If the data on XOMA 052 continue to impress, the company should be able to attract a partner. Hopefully...."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next